GAMMA Investing LLC Has $85,000 Holdings in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS)

GAMMA Investing LLC lifted its holdings in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 453.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,598 shares of the company’s stock after purchasing an additional 24,252 shares during the quarter. GAMMA Investing LLC’s holdings in COMPASS Pathways were worth $85,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CMPS. RTW Investments LP bought a new stake in shares of COMPASS Pathways in the fourth quarter worth $11,714,000. Altium Capital Management LLC bought a new stake in COMPASS Pathways during the fourth quarter worth $5,384,000. Tang Capital Management LLC bought a new stake in COMPASS Pathways during the fourth quarter worth $3,780,000. Nantahala Capital Management LLC raised its position in COMPASS Pathways by 400.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock worth $3,780,000 after acquiring an additional 800,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in COMPASS Pathways during the fourth quarter worth $2,458,000. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Trading Up 7.7%

NASDAQ CMPS opened at $2.53 on Wednesday. The stock has a market capitalization of $236.71 million, a price-to-earnings ratio of -1.27 and a beta of 2.25. COMPASS Pathways PLC Sponsored ADR has a one year low of $2.25 and a one year high of $8.54. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.18 and a quick ratio of 10.18. The business’s fifty day moving average is $4.07 and its 200-day moving average is $3.87.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. Equities research analysts predict that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

Analysts Set New Price Targets

CMPS has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of COMPASS Pathways in a report on Monday, May 12th. Stifel Nicolaus assumed coverage on shares of COMPASS Pathways in a research note on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target on the stock. Canaccord Genuity Group decreased their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Evercore ISI restated an “in-line” rating and issued a $6.00 price target (down from $11.00) on shares of COMPASS Pathways in a research note on Monday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $12.00 price target on shares of COMPASS Pathways in a research note on Tuesday, May 27th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $17.00.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.